Buscar
Mostrando ítems 1-5 de 5
Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients
(Elsevier, 2017-01-18)
[Abstract] Background. New direct-acting antivirals agents (DAAs) are very safe and well tolerated.
Objectives. The purpose of this study is to analyse the efficacy and safety of DAAs in elderly patients, who have ...
Effectiveness and Safety of Direct‐Acting Antivirals in Hepatitis C Infected Patients With Mental Disorders: Results in Real Clinical Practice
(Willey Online Library, 2020-03-17)
[Abstract]
The aim of this study is to analyze the effectiveness and safety of direct‐acting antivirals (DAAs) in psychiatric patients with chronic hepatitis C (CHC). Secondary objectives included adherence and drug‐drug ...
Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients: results in real clinical practice
(Sociedad Española de Quimioterapia, 2019)
[Abstract] OBJECTIVE: Direct-acting antivirals have shown high efficacy in all hepatitis C virus (HCV) genotypes, but genotype 3 (G3) treatments continue to be a challenge, mainly in cirrhotic patients. The aim of this ...
Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals
(Plos ONE, 2019-06-03)
[Abstract] BACKGROUND:
Direct-acting antivirals (DAAs) are effective in patients aged ≥65 years. However, little is known about the effects of DAAs on survival, liver decompensation and development of hepatocellular ...
Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients
(BMJ Publishing Group, 2020-02-07)
[Abstract]
Objectives. Sofosbuvir/velpatasvir±ribavirin (SOF/VEL±RBV) and glecaprevir/pibrentasvir (GLE/PIB) are the drug combinations of choice for treating individuals with genotype 3 hepatitis C virus (G3-HCV) infection. ...